Nature Communications (Mar 2022)
A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens
- Kade D. Roberts,
- Yan Zhu,
- Mohammad A. K. Azad,
- Mei-Ling Han,
- Jiping Wang,
- Lynn Wang,
- Heidi H. Yu,
- Andrew S. Horne,
- Jo-Anne Pinson,
- David Rudd,
- Nicolas H. Voelcker,
- Nitin A. Patil,
- Jinxin Zhao,
- Xukai Jiang,
- Jing Lu,
- Ke Chen,
- Olga Lomovskaya,
- Scott J. Hecker,
- Philip E. Thompson,
- Roger L. Nation,
- Michael N. Dudley,
- David C. Griffith,
- Tony Velkov,
- Jian Li
Affiliations
- Kade D. Roberts
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Yan Zhu
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Mohammad A. K. Azad
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Mei-Ling Han
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Jiping Wang
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Lynn Wang
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Heidi H. Yu
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Andrew S. Horne
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
- Jo-Anne Pinson
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
- David Rudd
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
- Nicolas H. Voelcker
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
- Nitin A. Patil
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Jinxin Zhao
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Xukai Jiang
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Jing Lu
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Ke Chen
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- Olga Lomovskaya
- Qpex Biopharma, Inc.
- Scott J. Hecker
- Qpex Biopharma, Inc.
- Philip E. Thompson
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
- Roger L. Nation
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
- Michael N. Dudley
- Qpex Biopharma, Inc.
- David C. Griffith
- Qpex Biopharma, Inc.
- Tony Velkov
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
- Jian Li
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University
- DOI
- https://doi.org/10.1038/s41467-022-29234-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
Polymyxins are often the last therapeutic option for multidrug-resistant (MDR) bacteria, but have suboptimal safety and efficacy. Here the authors report the discovery and development of a synthetic lipopeptide with an improved safety and efficacy against top-priority MDR Gram-negative pathogens.
